Document Detail

Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.
Jump to Full Text
MedLine Citation:
PMID:  24868239     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Protein phosphatase 2A (PP2A) is an important phosphatase which regulates various cellular processes, such as protein synthesis, cell growth, cellular signaling, apoptosis, metabolism, and stress responses. It is a holoenzyme composed of the structural A and catalytic C subunits and a regulatory B subunit. As an environmental toxin, okadaic acid, is a tumor promoter and binds to PP2A catalytic C subunit and the cancer-associated mutations in PP2A structural A subunit in human tumor tissue; PP2A may have tumor-suppressing function. It is a potential drug target in the treatment of cancer. In this study, we screen the TCM compounds in TCM Database@Taiwan to investigate the potent lead compounds as PP2A agent. The results of docking simulation are optimized under dynamic conditions by MD simulations after virtual screening to validate the stability of H-bonds between PP2A- α protein and each ligand. The top TCM candidates, trichosanatine and squamosamide, have potential binding affinities and interactions with key residues Arg89 and Arg214 in the docking simulation. In addition, these interactions were stable under dynamic conditions. Hence, we propose the TCM compounds, trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein.
Authors:
Kuan-Chung Chen; Hsin-Yi Chen; Calvin Yu-Chian Chen
Related Documents :
23911089 - Redox-linked domain movements in the catalytic cycle of cytochrome p450 reductase.
19556119 - Fabrication and characterization of a multiwell array sers chip with biological applica...
23223529 - Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria ve...
24982189 - Structural basis for the recruitment of glycogen synthase by glycogenin.
23466229 - Pf-04859989 as a template for structure-based drug design: identification of new pyrazo...
23846529 - Structural analysis of protein z gene variants in patients with foetal losses.
10439069 - Crystal structure of bullfrog m ferritin at 2.8 a resolution: analysis of subunit inter...
11060019 - Carboxyl methylation regulates phosphoprotein phosphatase 2a by controlling the associa...
23421589 - Rational discovery of dengue type 2 non-competitive inhibitors.
Publication Detail:
Type:  Journal Article     Date:  2014-04-29
Journal Detail:
Title:  Evidence-based complementary and alternative medicine : eCAM     Volume:  2014     ISSN:  1741-427X     ISO Abbreviation:  Evid Based Complement Alternat Med     Publication Date:  2014  
Date Detail:
Created Date:  2014-05-28     Completed Date:  2014-05-28     Revised Date:  2014-05-30    
Medline Journal Info:
Nlm Unique ID:  101215021     Medline TA:  Evid Based Complement Alternat Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  436863     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Evid Based Complement Alternat Med
Journal ID (iso-abbrev): Evid Based Complement Alternat Med
Journal ID (publisher-id): ECAM
ISSN: 1741-427X
ISSN: 1741-4288
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2014 Kuan-Chung Chen et al.
open-access:
Received Day: 18 Month: 1 Year: 2014
Accepted Day: 30 Month: 1 Year: 2014
Print publication date: Year: 2014
Electronic publication date: Day: 29 Month: 4 Year: 2014
pmc-release publication date: Day: 29 Month: 4 Year: 2014
Volume: 2014E-location ID: 436863
PubMed Id: 24868239
ID: 4020536
DOI: 10.1155/2014/436863

Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer
Kuan-Chung Chen1 http://orcid.org/0000-0003-0223-1577
Hsin-Yi Chen2
Calvin Yu-Chian Chen234*
1School of Pharmacy, China Medical University, Taichung 40402, Taiwan
2Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
3School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan
4Computational and Systems Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Correspondence: *Calvin Yu-Chian Chen: ycc929@mit.edu
[other] Academic Editor: Fuu-Jen Tsai

1. Introduction

Protein phosphatase 2A (PP2A) is an important phosphatase which consists of a holoenzyme composed of the structural A and catalytic C subunits and a regulatory B subunit [13]. As each of these subunits exists many different isoforms, the holoenzymes of PP2A, can form various distinct trimeric ABC complexes. This enzyme can regulate various cellular processes, such as protein synthesis, cell growth, cellular signaling, apoptosis, metabolism, and stress responses [4, 5]. Many researches indicate the cancer-associated mutations in PP2A structural A subunit in human tumor tissue [68]. As a research in 1988 determined that an environmental toxin, okadaic acid, is a tumor promoter and binds to PP2A catalytic C subunit [9], PP2A may have tumor-suppressing function. As PP2A has tumor-suppressing function, it is a potential drug target in the treatment of cancer [10, 11].

Nowadays, the researchers have determined more and more distinct mechanisms of diseases [1218]. According to these mechanisms, the researchers can identify the potential target protein for drug design against each disease [1922]. The compounds extracted from traditional Chinese medicine (TCM) have been indicated in many in silico researches as potential lead compounds for the treatment of many different diseases, including tumours [2326], diabetes [27], inflammation [28], influenza [29], metabolic syndrome [30], stroke [3133], viral infection [34], and some other diseases [35, 36]. In this study, we aim to improve drug development of TCM compounds by investigating the potent lead compounds as PP2A agent from the TCM compounds in TCM Database@Taiwan [37]. As the disordered amino acids in the protein may cause the side effect and reduce the possibility of ligand binding to target protein [38, 39], we have predicted the disordered residues in sequence of PP2A-α protein before virtual screening. After virtual screening of the TCM compounds, the results of docking simulation are optimized under dynamic conditions by MD simulations to validate the stability of H-bonds between PP2A-α protein and each ligand.


2. Materials and Methods
2.1. Data Collection

The X-ray crystallography structure of the human serine/threonine-protein phosphatase 2A (PP2A) catalytic subunit alpha isoform was obtained from RCSB Protein Data Bank with PDB ID: 3FGA [40]. We employed PONDR-Fit [41] protocol to predict the disordered residues in sequence of PP2A-α protein from Swiss-Prot (UniProtKB: P67775). For preparation, the protein was protonated with Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field [42], and the crystal water was removed using Prepare Protein module in Discovery Studio 2.5 (DS2.5). The volume of the cocrystallized PP2A inhibitor, microcysteine, was employed to define the binding site for virtual screening. TCM compounds from TCM Database@Taiwan [37] were protonated using Prepare Ligand module in DS2.5 and filtered by Lipinski's Rule of Five [43] before virtual screening.

2.2. Docking Simulation

For virtual screening, the TCM compounds were docked into the binding site using a shape filter and Monte-Carlo ligand conformation generation using LigandFit protocol [44] in DS2.5. The docking poses were then optionally minimized with CHARMM force field [42] and then calculated their Dock Score energy function by the following equation:

[Formula ID: eq1]
(1) 
Dock  Score=−(ligand/receptor  interaction  energy   +ligand  internal  energy).

Finally, the similar poses were rejected using the clustering algorithm.

2.3. Molecular Dynamics (MD) Simulation

The molecular dynamics (MD) simulation for each protein-ligand complex under dynamic conditions was performed by Gromacs 4.5.5 [45]. The topology and parameters for PP2A-α protein with charmm27 force field and ligands were performed by the pdb2gmx protocol of Gromacs and SwissParam program [46], respectively. Gromacs performed a cubic box with edge approx 12 Å from the molecules periphery and solvated with TIP3P water model for each protein-ligand complex. The common minimization algorithm, Steepest descents [47], was employed with a maximum of 5,000 steps to remove bad van der Waals contacts. After a neutral system using 0.145 M NaCl model was created by Gromacs; the steepest descents minimization with a maximum of 5,000 steps was employed again to remove bad van der Waals contacts. For the equilibration, the Linear Constraint algorithm for all bonds was employed for the position-restrained molecular dynamics with NVT equilibration, Berendsen weak thermal coupling method, and Particle Mesh Ewald method. A total of 5000 ps production simulation was then performed with time step in unit of 2 fs under Particle Mesh Ewald (PME) option and NPT ensembles. The 5000 ps of MD trajectories was then analyzed using a series of protocols in Gromacs.


3. Results and Discussion
3.1. Disordered Protein Prediction

The result of the disordered residues predicted by PONDR-Fit with the sequence of PP2A-α protein from Swiss-Prot (UniProtKB: P67775) is illustrated in Figure 1. For PP2A-α protein, Figure 1 indicates that the structure of binding domain is stable as the major residues of binding domain do not lie in the disordered region.

3.2. Docking Simulation

For virtual screening, Dock Score energy function is used to rank the top potential TCM compounds; the chemical scaffold of top four TCM candidates with high binding affinity is displayed in Figure 2 with its scoring function and sources. The top four TCM compounds, trichosanatine, angeliferulate, dichotomoside E, and squamosamide, were extracted from Trichosanthes rosthornii Harms, Angelica sinensis, Stellaria dichotoma L., and Annona squamosa L., respectively. After the virtual screening, the docking poses of top four TCM compounds in the binding domain of PP2A-α are displayed in Figure 3. All the top four TCM compounds have interactions with key residues Arg89 and Arg214. Trichosanatine exists hydrogen bonds (H-bonds) with key residues Arg89 and Arg214. Angeliferulate has H-bonds with residues Arg89, Gln122, Arg214, and a π interaction with residue Trp200. Dichotomoside E forms H-bonds with residues Arg89, Tyr127, Gly215, and a π interaction with residue Arg214. Squamosamide has both H-bond and π interaction with residue Arg214. In addition, there exist H-bonds with residue Leu243 and a π interaction with residue Arg89. Those interactions hold the top four TCM compounds in the binding domain of PP2A-α protein.

3.3. Molecular Dynamics Simulation

In LigandFit protocol, each compound was docked into binding site using a shape-based docking with rigid body of PP2A-α protein. The interactions between each compound and PP2A-α protein mention above may not be stable under dynamic conditions. We employed MD simulation for each protein-ligand complex to study the stability of interactions for each docking pose. The information of root-mean-square deviations (RMSDs) and total energies over 5000 ps of MD simulation is displayed in Figure 4. It indicates that the atomic fluctuations of protein complexes with top four TCM compounds tend to be stable after 4800 ps of MD simulation, and there is no significant variation in the total energies for each complex during MD simulation. To analyze the possible effect of each top TCM candidate for the PP2A-α protein, Figure 5 displays the variation of solvent accessible surface area for PP2A-α protein over 5000 ps of MD simulation. For top four TCM candidates, they have similar hydrophobic and hydrophilic surface areas when the MD simulation tends to be stable, which indicates that those compounds may not affect the sharpness of PP2A-α protein after they dock in the binding domain. Figure 6 illustrates the root-mean-square fluctuation of each residue of PP2A-α protein during 5000 ps of MD simulation. It indicates that they have similar deviation for key residues in the binding domain of PP2A-α protein during 5000 ps of MD simulation. In Figure 7, root-mean-square deviation value for each PP2A-α protein complex illustrates the RMSD values between each MD trajectory of 5000 ps of MD simulation, and graphical depiction of the clusters with cutoff 0.1 nm is employed to define the middle RMSD structure in the major cluster as the representative structures for each complex after MD simulation. The docking poses of the representative structures for each protein-ligand complex are illustrated in Figure 8. For angeliferulate and dichotomoside E, the interactions between protein and ligand mention in docking simulation are not stable under dynamic conditions, which indicates that those two TCM compounds cannot binding stabilized in the binding domain of PP2A-α protein. For trichosanatine, the representative docking poses in 4.82 ns indicate that it has similar docking pose as mentioned in docking simulation and maintains the H-bond with key residue Arg89. In addition, it forms H-bonds and π interactions with residues His118, Tyr127, and Trp200 after MD simulation. The docking pose of squamosamide in 4.82 ns of MD simulation also has similar docking pose as mentioned in docking simulation and maintains the H-bond and π interactions with key residue Arg214 and H-bond with Leu243. To analyze the stability of these H-bonds, the occupancy of H-bonds overall 5000 ps of molecular dynamics simulation are listed in Table 1, and the variations of distance for each H-bond in the PP2A-α protein complexes with trichosanatine and squamosamide are illustrated in Figure 9. For trichosanatine, it has stable H-bonds with residues Arg89 and His118, and the distances with residues Arg214 are stable in 0.4 nm. For squamosamide, it has stable H-bonds with residues Arg214 and Leu243.


4. Conclusion

This study aims to investigate the potent TCM candidates as lead compounds of agent for PP2A-α protein. The top four TCM compounds have high binding affinities with PP2A-α protein in the docking simulation. However, the results of docking simulation are optimized under dynamic conditions by MD simulations to validate the stability of H-bonds between PP2A-α protein and each ligand. Although angeliferulate and dichotomoside E have potent binding affinities with PP2A-α protein in the docking simulation, the interactions between protein and ligand mentioned in docking simulation are not stable under dynamic conditions. For the other two top TCM candidates, trichosanatine and squamosamide, there exist stable interactions with key residues Arg89 and Arg214 under dynamic conditions. Hence, we propose the TCM compounds, trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A-α protein.


Acknowledgments

The research was supported by Grants from the National Science Council of Taiwan (NSC102-2325-B039-001 and NSC102-2221-E-468-027-), Asia University (Asia101-CMU-2 and 102-Asia-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03).

Conflict of Interests

The authors declared that there is no conflict of interests.

Authors' Contribution

Kuan-Chung Chen and Hsin-Yi Chen had equal contribution.


References
1. Porter IM,Schleicher K,Porter M,Swedlow JR. Bod1 regulates protein phosphatase 2A at mitotic kinetochoresNature CommunicationsYear: 20134article 2677
2. Wera S,Hemmings BA. Serine/threonine protein phosphatasesThe Biochemical JournalYear: 1995311part 117292-s2.0-00291295577575450
3. Mumby MC,Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growthPhysiological ReviewsYear: 19937346736992-s2.0-00271437258415923
4. Janssens V,Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signallingThe Biochemical JournalYear: 2001353part 34174392-s2.0-003525289411171037
5. Virshup DM. Protein phosphatase 2A: a panoply of enzymesCurrent Opinion in Cell BiologyYear: 20001221801852-s2.0-003400938910712915
6. Ruediger R,Hentz M,Fait J,Mumby M,Walter G. Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigensJournal of VirologyYear: 19946811231292-s2.0-00280822998254721
7. Calin GA,di Iasio MG,Caprini E,et al. Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasmsOncogeneYear: 2000199119111952-s2.0-003470825710713707
8. Ruediger R,Pham HT,Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit geneOncogeneYear: 200120110152-s2.0-003580421711244497
9. Bialojan C,Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kineticsBiochemical JournalYear: 198825612832902-s2.0-00236917312851982
10. Chen W,Wang Z,Jiang C,Ding Y. PP2A-mediated anticancer therapyGastroenterology Research and PracticeYear: 2013201310 pages675429
11. Schönthal AH. Role of serine/threonine protein phosphatase 2A in cancerCancer LettersYear: 200117011132-s2.0-003584044611448528
12. Jiang Y,Li X,Yang W,et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cellsMolecular CellYear: 2014531758724316223
13. Chou I-C,Lin W-D,Wang C-H,et al. Association analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese childrenBioMedicineYear: 2013328891
14. Yamamoto T,Hung W-C,Takano T,Nishiyama A. Genetic nature and virulence of community-associated methicillin-resistant Staphylococcus aureusBioMedicineYear: 201331218
15. Wang C-H,Lin W-D,Bau D-T,Choua I-C,Tsai C-H,Tsai F-J. Appearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathwayBioMedicineYear: 2013328287
16. Chang Y-M,Velmurugan BK,Kuo W-W,et al. Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cellsBioMedicineYear: 201334148152
17. Leung YM,Wong KL,Chen SW,et al. Down-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cellsBioMedicineYear: 201333130139
18. Mahamuni SP,Khose RD,Menaa F,Badole SL. Therapeutic approaches to drug targets in hyperlipidemiaBioMedicineYear: 201224137146
19. Jao C-L,Huang S-L,Hsu K-C. Angiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effectsBioMedicineYear: 201224130136
20. Lin M-C,Tsai S-Y,Wang F-Y,Liu F-H,Syu J-N,Tang F-Y. Leptin induces cell invasion and the upregulation of matrilysin in human colon cancer cellsBioMedicineYear: 201334174180
21. Su K-P. Inflammation in psychopathology of depression: clinical, biological, and therapeutic implicationsBioMedicineYear: 20122268742-s2.0-84860591476
22. Leissring MA,Malito E,Hedouin S,et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulinPLoS ONEYear: 201055p. e105042-s2.0-77956274306
23. Chen C-Y,Chen CY-C. Insights into designing the dual-targeted HER2/HSP90 inhibitorsJournal of Molecular Graphics & ModellingYear: 201029121312-s2.0-7795577255220471294
24. Yang S-C,Chang S-S,Chen H-Y,Chen CY-C. Identification of potent EGFR inhibitors from TCM database@TaiwanPLoS Computational BiologyYear: 20117102-s2.0-80055077153e1002189
25. Tsou YA,Chen KC,Lin HC,Chang SS,Chen CYC. Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics studyPLoS ONEYear: 2012711e50087
26. Tsou YA,Chen KC,Chang SS,Wen YR,Chen CY. A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitorsJournal of Biomolecular Structure & DynamicsYear: 201331121358136923140436
27. Chen KC,Chang SS,Tsai FJ,Chen CY. Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?Journal of Biomolecular Structure & DynamicsYear: 201331111219123523146021
28. Chen K-C,Sun M-F,Yang S-C,et al. Investigation into potent inflammation inhibitors from traditional Chinese medicineChemical Biology & Drug DesignYear: 20117846796882-s2.0-8005261917421801310
29. Chang S-S,Huang H-J,Chen CY-C. Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicinePLoS Computational BiologyYear: 20117122-s2.0-84855282742e1002315
30. Chen KC,Chang SS,Huang HJ,Lin TL,Wu YJ,Chen CY. Three-in-one agonists for PPAR-alpha, PPAR-gamma, and PPAR-delta from traditional Chinese medicineJournal of Biomolecular Structure & DynamicsYear: 201230666268322731403
31. Chen K-C,Yu-Chian Chen C. Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approachSoft MatterYear: 201178400140082-s2.0-79953746295
32. Chen K-C,Chang K-W,Chen H-Y,Chen CY-C. Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?Molecular BioSystemsYear: 201179271127192-s2.0-8005176068421796302
33. Chang T-T,Chen K-C,Chang K-W,et al. In silico pharmacology suggests ginger extracts may reduce stroke risksMolecular BioSystemsYear: 201179270227102-s2.0-8005176719521776525
34. Huang HJ,Jian YR,Chen CY. Traditional Chinese medicine application in HIV: an in silico studyJournal of Biomolecular Structure & DynamicsYear: 201432111223252879
35. Tou WI,Chang SS,Lee CC,Chen CY. Drug design for neuropathic pain regulation from traditional Chinese medicineScientific ReportsYear: 20133article 844
36. Chen KC,Jian YR,Sun MF,Chang TT,Lee CC,Chen CY. Investigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese MedicineJournal of Biomolecular Structure & DynamicsYear: 201331111207121823075283
37. Chen CY-C. TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silicoPLoS ONEYear: 2011612-s2.0-79251561193e15939
38. Tou WI,Chen CY. May disordered protein cause serious drug side effect?Drug Discovery TodayYear: 2013
39. Chen CY,Tou WI. How to design a drug for the disordered proteins?Drug Discovery TodayYear: 20131819-2091091523643489
40. Xu Z,Cetin B,Anger M,et al. Structure and function of the PP2A-shugoshin interactionMolecular CellYear: 20093544264412-s2.0-6894920630819716788
41. Xue B,Dunbrack RL,Williams RW,Dunker AK,Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acidsBiochimica et Biophysica ActaYear: 20101804499610102-s2.0-7684908796820100603
42. Brooks BR,Bruccoleri RE,Olafson BD,States DJ,Swaminathan S,Karplus M. CHARMM: a program for macromolecular energy minimization and dynamics calculationsJournal of Computational ChemistryYear: 19834187217
43. Lipinski CA,Lombardo F,Dominy BW,Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery ReviewsYear: 2001461–33262-s2.0-003528977911259830
44. Venkatachalam CM,Jiang X,Oldfield T,Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sitesJournal of Molecular Graphics and ModellingYear: 20032142893072-s2.0-003721210212479928
45. Hess B,Kutzner C,van der Spoel D,Lindahl E. GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulationJournal of Chemical Theory and ComputationYear: 2008434354472-s2.0-46249092554
46. Zoete V,Cuendet MA,Grosdidier A,Michielin O. SwissParam: a fast force field generation tool for small organic moleculesJournal of Computational ChemistryYear: 20113211235923682-s2.0-7995884170321541964
47. Fletcher R. OptimizationYear: 1969New York, NY, USAAcademic Press

Article Categories:
  • Research Article


Previous Document:  Color distribution differences in the tongue in sleep disorder.
Next Document:  The Analysis of Surface EMG Signals with the Wavelet-Based Correlation Dimension Method.